Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 12'th Aug 2024
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript
09:23pm, Thursday, 08'th Aug 2024
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head of Investor Relations Scott Struthers - Founder an
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
07:01pm, Thursday, 08'th Aug 2024
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.94 per share a year ago.
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
08:30am, Thursday, 08'th Aug 2024
ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care ACRO/TRUTH Provides
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Thursday, 01'st Aug 2024
Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
04:05pm, Thursday, 18'th Jul 2024
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:29pm, Wednesday, 10'th Jul 2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted n
7 Biotech Stocks to Boost Your Portfolio to Peak Health
02:11pm, Wednesday, 26'th Jun 2024
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:35pm, Monday, 10'th Jun 2024
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted n
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg)
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.
04:05pm, Thursday, 30'th May 2024
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr.
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
08:00am, Wednesday, 22'nd May 2024
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript
10:09am, Saturday, 11'th May 2024
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive
